Having trouble accessing articles? Reset your cache.

Analyst picks & changes

Analyst picks & changes

Company Bank Analyst Coverage Opinion Wk chg 4/16 cls
Acorda Therapeutics Inc. (NASDAQ:ACOR) Leerink Joshua Schimmer Upgrade Market outperform (from market perform) 7% $37.85
Schimmer upgraded based on feedback from multiple sclerosis specialists indicating Ampyra dalfampridine is "launching quickly and penetrating deeply in a highly concentrated MS population." He increased his sales estimate for 2010 and

Read the full 743 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE